About this trial
Sarcopenia or muscle loss and function is a component of the frailty syndrome. In this sense, frailty is becoming an important risk factor in predicting outcomes after major surgery and is defined as a geriatric syndrome of decreased reserve and resiliency to stressors that have been associated with adverse health outcomes in older adults. Despite its potentially relevant role in predicting postoperative recovery, frailty is rarely evaluated before surgery, and this is partially due to the low reliability of the most used frailty scores. Therefore, improvement in the frailty evaluation would be beneficial during the preoperative assessment of major surgeries. Sarcopenia, or the decline of skeletal muscle tissue with age, is one of the most important causes of functional decline and loss of independence in older adults and low muscle mass is a core component of frailty that has the advantage of being objectively quantifiable regardless of mobility, disability, or illness acuity. Psoas Muscle (PM) mass is an important parameter for evaluating muscle mass and has been previously correlated to frailty with a negative impact on the postoperative outcomes after major surgery and Psoas Muscle mass Index (PMI) is an easily available parameter for evaluating muscle mass and has already been demonstrated to be effective in predicting outcomes in different clinical settings. PMI has also been shown to be an effective predictor of outcomes in cardiac surgery although there are no studies specifically focusing on minimally invasive cardiac surgery. With this study, the investigators aim to investigate the relevance of PMI as a predictor of postoperative mobilisation, hospital length of stay and clinical recovery after major cardiac surgery conducted via a minimally invasive approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Elderly patients (≥ 65 years old)
Able to take consent
Listed for minimally invasive cardiac surgery
Elective and urgent procedures included
Disqualifiers
Full median sternotomy approach
Emergency procedures
Unable to take consent
Unable to undergo MRI
Trial population
Cardiac surgery patients undergoing heart valve surgery via a minimally invasive approach
Trial design
Cohort
Prospective
Treatments tested in this trial
Lower Abdomen MRI
Other interventionThe patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
Treatment groups
Trial outcomes
Primary outcomes
Postoperative Intensive care unit (ITU) stay
Total number of hours spent in ITU after the primary (indexed) cardiac operation
Postoperative overall length of stay
Total number of days spent in hospital after the primary (indexed) cardiac operation
Mobilization time
Time to mobilization after the primary (indexed) cardiac operation defined as standing up or sitting down for at least 3 consecutive hours
Secondary outcomes
Postoperative mortality
In hospital mortality after the primary (indexed) cardiac operation
Long term mortality
Mortality at the latest follow up after the primary (indexed) cardiac operation
Postoperative Complications
Any surgical related postoperative complication related to the primary (indexed) cardiac operation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: